2m 2m 2m 2m 2m 2m 2m
OLEMA PHARMA (OLMA)
NASDAQ
$10.63+$0.10 (+0.95%)
Price as of Jun 23, 2026 5:53 PM EDT- $873.5MMarket Cap
- 124.52%1-Year Change
- BiotechnologyIndustry
OLEMA PHARMA (OLMA)
$10.63+$0.10 (+0.95%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -157.7M +26.65% | -124.5M +44.55% | -86.1M +4.70% | -82.3M +61.01% | |
Depreciation and Amortization Expense | 490,000 +24.68% | 393,000 +4.24% | 377,000 +5.60% | 357,000 +119.02% | |
Total Operating Expenses | 178.7M +25.62% | 142.3M +35.53% | 105.0M -1.89% | 107.0M +49.65% | |
Operating Profit | -178.7M +25.62% | -142.3M +35.53% | -105.0M -1.89% | -107.0M +49.65% | |
Interest Income | 16.2M +27.93% | 12.7M +52.34% | 8.3M +273.65% | 2.2M +404.07% | |
Interest Expense | -100,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 16.1M +27.14% | 12.7M +52.34% | 8.3M +273.65% | 2.2M +1,155.92% | |
Total Nonoperating Income and Expense | 16.2M +27.09% | 12.8M +53.91% | 8.3M +277.37% | 2.2M +457.22% | |
Income before Taxes | -178.7M +25.62% | -142.3M +35.53% | -105.0M -1.89% | -107.0M +50.48% | |
Income Taxes | 3,000 +50.00% | 2,000 0.00% | 2,000 +100.00% | 1,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -162.5M +25.47% | -129.5M +33.95% | -96.7M -7.76% | -104.8M +47.39% | |
Net Income from Continuing Operations Applicable to Common | -162.5M +25.47% | -129.5M +33.95% | -96.7M -7.76% | -104.8M +47.39% | |
Basic EPS and Net Income | -1.87 -15.00% | -2.20 +2.80% | -2.14 -18.32% | -2.62 +45.56% | |
Diluted EPS and Net Income | -1.87 -15.00% | -2.20 +2.80% | -2.14 -18.32% | -2.62 +45.56% | |
Basic Weighted Average Shares | 87.0M +48.11% | 58.7M +29.83% | 45.2M +13.13% | 40.0M +1.19% | |
Diluted Weighted Average Shares | 87.0M +48.11% | 58.7M +29.83% | 45.2M +13.13% | 40.0M +1.19% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 48.3M -65.37% | 139.5M +103.50% | 68.5M +189.17% | 23.7M +71.60% | |
Short-Term Investments | 457.1M +55.17% | 294.6M +52.43% | 193.3M +6.94% | 180.7M -33.91% | |
Cash and Cash Equivalents and Short-Term Investments | 505.4M +16.44% | 434.1M +65.80% | 261.8M +28.07% | 204.4M -28.84% | |
Total Current Assets | 515.5M +17.56% | 438.5M +64.52% | 266.5M +27.58% | 208.9M -28.14% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | 581,000 +159.38% | |
Property and Plant and Equipment and Net | 274,000 -63.27% | 746,000 -22.93% | 968,000 -34.59% | 1.5M +0.41% | |
Total Long-Term Assets | 15,000 0.00% | 15,000 -98.45% | 968,000 -65.07% | 2.8M +413.15% | |
Total Assets | 533.4M +18.28% | 451.0M +62.84% | 276.9M +28.43% | 215.6M -27.13% | |
Income Taxes Payable | N/A N/A | 41,000 -43.84% | 73,000 +8.96% | 67,000 -23.86% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 51.8M +24.05% | 41.8M +93.14% | 21.6M +30.65% | 16.5M +83.49% | |
Total Long-Term Debt | 3.0M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 69,000 -73.15% | 257,000 -82.02% | 1.4M -7.81% | 1.6M -34.27% | |
Total Liabilities | 54.9M +30.60% | 42.0M +82.28% | 23.1M +27.36% | 18.1M +59.08% | |
Retained Earnings | -597.6M +37.34% | -435.1M +42.36% | -305.6M +46.25% | -209.0M +100.57% | |
Total Stockholders Equity | 478.6M +17.02% | 409.0M +61.08% | 253.9M +28.52% | 197.5M -30.58% | |
Total Shares Outstanding | 81.4M +9.51% | 74.3M +35.13% | 55.0M +36.50% | 40.3M +1.23% | |
Cash Flow | |||||
Cash from Operating Activities | -146.7M +40.60% | -104.4M +24.63% | -83.7M +2.03% | -82.1M +61.90% | |
Capital Expenditures | 159,000 0.00% | 159,000 -56.20% | 363,000 0.00% | 363,000 -76.95% | |
Cash from Investing Activities | -155.8M +66.54% | -93.5M +1,827.97% | -4.9M -105.30% | 91.5M +133.21% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 211.3M -21.40% | 268.8M +101.49% | 133.4M +27,928.36% | 476,000 -65.78% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -33.00% -7.22% | -35.57% -9.35% | -39.24% -4.20% | -40.97% N/A | |
Return on Equity | -36.61% -6.29% | -39.07% -8.77% | -42.82% -1.49% | -43.47% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 9.95 -5.24% | 10.50 -14.82% | 12.33 -2.35% | 12.62 N/A | |
Cash Ratio | 0.93 -72.09% | 3.34 +5.37% | 3.17 +121.34% | 1.43 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow